# Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

> **NCT00280007** · PHASE2 · TERMINATED · sponsor: **Medical University of Vienna** · enrollment: 32 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00280007
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2009-12
- **Final completion:** 2010-12
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Safety concerns in the treatment arm
- **Last updated:** 2010-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280007, "Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00280007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*